Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Creso Pharma (CPH) has introduced a remote working policy to curb the workplace impact of COVID-19
  • The majority of Creso’s staff in Sydney and Switzerland are now working from home
  • Additionally, the company’s Canadian Mernova Medical Facility has implemented a shift timetable and appointed a social distance coordinator to help manage everyone’s workload
  • In the meantime, Creso is continuing to progress towards securing a European Union Good Manufacturing Practice (EU GMP) certification
  • This will allow Mernova to begin exporting its cannabis flower and oil into European markets
  • Creso is down slightly on the market this afternoon, trading for 5.9¢ per share

Creso Pharma (CPH) has introduced a remote working policy to curb the workplace impact of COVID-19.

“Creso Pharma is continuing to monitor the situation as it unfolds and is taking precautionary steps to prepare for the potential impacts a continued disturbance may have on supply chains and sales,” CEO Miri Halperin Wernli said.

Saftey and cost-reduction methods

Under Creso’s remote working policy, the majority of its staff in Sydney and Switzerland are now working from home. Travel and social distancing measures are been promoted by all staff.

Mernova

Mernova has begun operating three shifts a day with specific start and finish times to minimise contact between employees, while the facility is able to maintain production levels.

The company said a social distance coordinator has been appointed to enforce the recommendations for social distancing at all times.

The facility is also taking steps to manage less essential production tasks and is implementing all administration staff work from home.

Creso also said non-essential contractors and other third parties are not permitted on the site.

Rising demand for Mernova’s products

Despite the challenging environment, Creso is working to maintain its business presence.

The company is also continuing to progress towards securing European Union Good Manufacturing Practice (EU GMP) certification. This EU GMP will allow Mernova to begin exporting its cannabis flower and oil into European markets.

The company expects to have further positive updates on this certification in the coming months.

“The COVID-19 pandemic will enhance our focus on continued operational improvements and efficiencies,” Miri said.

“Creso Pharma’s lean organisational structure means that our operations are not affected by international travel bans. We believe we all should do our part to slow the spread of the virus and we hope to see improvements in the global situation in the weeks ahead,” she added.

Creso is down slightly on the market this afternoon, trading for 5.9¢ per share.

CPH by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.